BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 25987643)

  • 1. Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response.
    Simmons B; Saleem J; Heath K; Cooke GS; Hill A
    Clin Infect Dis; 2015 Sep; 61(5):730-40. PubMed ID: 25987643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.
    Simmons B; Saleem J; Hill A; Riley RD; Cooke GS
    Clin Infect Dis; 2016 Mar; 62(6):683-694. PubMed ID: 26787172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients.
    ANRS CO13 HEPAVIH Cohort
    AIDS; 2015 Sep; 29(14):1821-30. PubMed ID: 26372388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits.
    Smith-Palmer J; Cerri K; Valentine W
    BMC Infect Dis; 2015 Jan; 15():19. PubMed ID: 25596623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
    van der Meer AJ; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Heathcote EJ; Manns MP; Kuske L; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
    JAMA; 2012 Dec; 308(24):2584-93. PubMed ID: 23268517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
    Berenguer J; Alvarez-Pellicer J; Martín PM; López-Aldeguer J; Von-Wichmann MA; Quereda C; Mallolas J; Sanz J; Tural C; Bellón JM; González-García J;
    Hepatology; 2009 Aug; 50(2):407-13. PubMed ID: 19575364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of achieving sustained virological response before hepatitis C virus-related hepatocellular carcinoma occurrence on survival and recurrence after curative surgical microwave ablation.
    Ryu T; Takami Y; Wada Y; Tateishi M; Matsushima H; Yoshitomi M; Mikagi K; Saitsu H
    Hepatol Int; 2018 Mar; 12(2):149-157. PubMed ID: 29488056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.
    Backus LI; Boothroyd DB; Phillips BR; Belperio P; Halloran J; Mole LA
    Clin Gastroenterol Hepatol; 2011 Jun; 9(6):509-516.e1. PubMed ID: 21397729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis.
    Cacoub P; Desbois AC; Comarmond C; Saadoun D
    Gut; 2018 Nov; 67(11):2025-2034. PubMed ID: 29703790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease.
    Backus LI; Belperio PS; Shahoumian TA; Mole LA
    Hepatology; 2018 Sep; 68(3):827-838. PubMed ID: 29377196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
    Cordero-Ruiz P; Carmona-Soria I; Rodríguez-Téllez M; Caunedo-Alvarez A; Quezada-Pacheco RH; Flores-Cucho A; Romero-Gómez M; Vilches-Arenas Á
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):792-799. PubMed ID: 28445251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection.
    van der Meer AJ; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Manns MP; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
    J Viral Hepat; 2014 Aug; 21(8):568-77. PubMed ID: 24118177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis.
    Bang CS; Song IH
    BMC Gastroenterol; 2017 Apr; 17(1):46. PubMed ID: 28376711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis.
    Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
    Liver Int; 2016 Jun; 36(6):817-26. PubMed ID: 26787002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short Communication: CXCL12 rs1029153 Polymorphism Is Associated with the Sustained Virological Response in HIV/Hepatitis C Virus-Coinfected Patients on Hepatitis C Virus Therapy.
    Pineda-Tenor D; Jiménez-Sousa MA; Rallón N; Berenguer J; Soriano V; Aldámiz-Echevarria T; García-Álvarez M; Diez C; Fernández-Rodríguez A; Benito JM; Resino S
    AIDS Res Hum Retroviruses; 2016 Mar; 32(3):226-31. PubMed ID: 26499461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
    Iqbal S; Yousuf MH; Yousaf MI
    World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B.
    Toyoda H; Kumada T; Tada T; Shimada N; Takaguchi K; Senoh T; Tsuji K; Tachi Y; Hiraoka A; Ishikawa T; Shima T; Okanoue T
    J Hepatol; 2017 Mar; 66(3):521-527. PubMed ID: 27890790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
    Mira JA; Rivero-Juárez A; López-Cortés LF; Girón-González JA; Téllez F; de los Santos-Gil I; Macías J; Merino D; Márquez M; Ríos-Villegas MJ; Gea I; Merchante N; Rivero A; Torres-Cornejo A; Pineda JA;
    Clin Infect Dis; 2013 Jun; 56(11):1646-53. PubMed ID: 23429381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care.
    Innes HA; Hutchinson SJ; Allen S; Bhattacharyya D; Bramley P; Delahooke TE; Dillon JF; Forrest E; Fraser A; Gillespie R; Goldberg DJ; Kennedy N; McDonald S; McLeod A; Mills PR; Morris J; Hayes P;
    Hepatology; 2011 Nov; 54(5):1547-58. PubMed ID: 22045672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection.
    Zoulim F; Moreno C; Lee SS; Buggisch P; Horban A; Lawitz E; Corbett C; Lenz O; Fevery B; Verbinnen T; Shukla U; Jessner W
    Virol J; 2018 Jan; 15(1):26. PubMed ID: 29378602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.